On September 13, China Chemical & Pharmaceutical Holdings held an online investor conference. The management team indicated that the company plans to drive future revenue growth through increased sales of pharmaceuticals and consumer products, as well as by expanding subsidiary locations. They expect to maintain a double-digit growth trajectory. Following the company’s transformation into a holdings structure, their focus over the next two years will be on growing revenue from new business units and improving operational efficiency. In response to a drop in stock prices after the company's re-listing following the transformation, they assured shareholders that a share buyback is under consideration to protect shareholder interests, though it still requires board approval.
China Chemical & Pharmaceutical Holdings re-listed on September 2 following its transformation. The company’s subsidiaries now include China Chemical & Pharmaceutical, a major domestic manufacturer of generic drugs, and two grandchild companies, Chunghwa Yuming Healthcare and Chunghwa Senior Care, both of which are expected to be directly held by the parent company within a year.
Tiffany Chen, spokesperson for China Chemical & Pharmaceutical Holdings, highlighted that China Chemical & Pharmaceutical obtained approval for five domestically produced and three imported drugs in the first half of the year. The company expects to add seven more products to its portfolio by the end of this year, with the number rising to 13 and 20 in the next two years, respectively. The proportion of specialized formulations in their product lineup is expected to increase annually.
For Chunghwa Yuming Healthcare, their cardiovascular drug OlmeCa achieved the top market share in Taiwan in the first half of the year, generating over NT$100 million in revenue. The company also secured orders from medical centers for their smart medication cabinets. In the area of senior care, Chunghwa Senior Care continues to expand its network of community-based home care stations, with a goal of establishing more than 12 stations across Taiwan.
China Chemical & Pharmaceutical Holdings stated that they expect the growth momentum from the first half of the year to continue into the second half, with double-digit growth anticipated for the full year. They are aiming to sustain stable, long-term double-digit growth going forward.
In response to shareholder questions about the company’s stock price decline after re-listing, which has now fallen below pre-transformation levels of China Chemical & Pharmaceutical before it was delisted, the management stated that they are considering a share buyback to safeguard shareholder interests. However, any decision on this will ultimately require board approval.
